2022

1. Teipel R, von Bonin M, Stolzel F, Schetelig J, Thiede C, Bornhauser M. [Relevance of clonal hematopoiesis for cellular therapies]. Inn Med (Heidelb). 2022;63(11):1126-1132.

2. Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Kruger T, Ruhnke L, Herold S, Stasik S, Sockel K, Middeke JM, Trautmann-Grill K, Bornhauser M, Thiede C, von Bonin M. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022;6(6):1941-1946.

3. Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Rollig C, Krug U, Kramer A, Scholl S, Hochhaus A, Brummendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schafer-Eckart K, Schliemann C, Krause SW, Hanel M, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Herold S, Stolzel F, Sockel K, von Bonin M, Muller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhauser M, Schetelig J, Thiede C. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139(1):87-103.

4. Stasik S, Kramer M, Zukunft S, Rollig C, Baldus CD, Platzbecker U, Serve H, Muller-Tidow C, Schafer-Eckart K, Kaufmann M, Krause S, Sauer T, Hanel M, Neubauer A, Ehninger G, Bornhauser M, Schetelig J, Middeke JM, Thiede C. Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD. Front Oncol. 2022;12:862991.

5. Stasik S, Burkhard-Meier C, Kramer M, Middeke JM, Oelschlaegel U, Sockel K, Ehninger G, Serve H, Muller-Tidow C, Baldus CD, Rollig C, Bornhauser M, Platzbecker U, Thiede C. Deep sequencing in CD34+ cells from peripheral blood allows sensitive detection of measurable residual disease in AML. Blood Adv. 2022.

6. Sidorova OA, Sayed S, Paszkowski-Rogacz M, Seifert M, Camgoz A, Roeder I, Bornhauser M, Thiede C, Buchholz F. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Cells. 2022;11(5).

7. Rucker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Dohner H, Thiede C, Dohner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022;36(1):90-99.

8. Rohnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause SW, Bucklein V, Hoffmann J, Jaramillo S, Schlenk RF, Rollig C, Bornhauser M, McCarthy N, Freeman S, Oelschlagel U, von Bonin M. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. Leukemia. 2022;36(9):2208-2217.

9. Middeke JM, Metzeler KH, Rollig C, Kramer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Kramer A, Hochhaus A, Brummendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Gorlich D, Sauerland C, Schafer-Eckart K, Schliemann C, Krause SW, Hanel M, Frickhofen N, Noppeney R, Kaiser U, Kaufmann M, Kunadt D, Wormann B, Sockel K, von Bonin M, Herold T, Muller-Tidow C, Platzbecker U, Berdel WE, Serve H, Baldus CD, Ehninger G, Schetelig J, Hiddemann W, Bornhauser M, Stolzel F, Thiede C. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Adv. 2022;6(5):1394-1405.

10. Kunadt D, Stasik S, Metzeler KH, Rollig C, Schliemann C, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Kramer A, Hochhaus A, Scholl S, Hilgendorf I, Brummendorf TH, Jost E, Steffen B, Bug G, Einsele H, Gorlich D, Sauerland C, Schafer-Eckart K, Krause SW, Hanel M, Hanoun M, Kaufmann M, Wormann B, Kramer M, Sockel K, Egger-Heidrich K, Herold T, Ehninger G, Burchert A, Platzbecker U, Berdel WE, Muller-Tidow C, Hiddemann W, Serve H, Stelljes M, Baldus CD, Neubauer A, Schetelig J, Thiede C, Bornhauser M, Middeke JM, Stolzel F, A. M. L. Cooperative Group SAL. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. J Hematol Oncol. 2022;15(1):126.

11. Kunadt D, Herold S, Poitz D, Wagenfuhr L, Kretschmann T, Sockel K, Ruhnke L, Bruckner S, Sommer U, Meier F, Rollig C, von Bonin M, Thiede C, Schetelig J, Bornhauser M, Stolzel F. Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation. Ther Adv Hematol. 2022;13:20406207221115005.

12. Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Gotze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Ades L. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO. Leukemia. 2022;36(10):2519-2527.

13. Kayser S, Kramer M, Martinez-Cuadron D, Grenet J, Metzeler KH, Sustkova Z, Luskin MR, Brunner AM, Elliott MA, Gil C, Marini SC, Racil Z, Cetkovsky P, Novak J, Perl AE, Platzbecker U, Stolzel F, Ho AD, Thiede C, Stone RM, Rollig C, Montesinos P, Schlenk RF, Levis MJ. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2022;107(4):836-843.

14. Jayavelu AK, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann DC, Wagner S, Donato E, Andresen C, Wilke AC, Zindel A, Jahn D, Splettstoesser B, Plessmann U, Munch S, Abou-El-Ardat K, Makowka P, Acker F, Enssle JC, Cremer A, Schnutgen F, Kurrle N, Chapuy B, Lober J, Hartmann S, Wild PJ, Wittig I, Hubschmann D, Kaderali L, Cox J, Brune B, Rollig C, Thiede C, Steffen B, Bornhauser M, Trumpp A, Urlaub H, Stegmaier K, Serve H, Mann M, Oellerich T. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. 2022;40(3):301-317 e312.

15. Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Ehninger G, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Thiede C, Stone RM, Dohner H, Dohner K. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. 2022;36(9):2218-2227.

16. Hernandez-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua SL, van der Salm E, Trautmann CL, Raffel S, Grunschlager F, Lutz R, Ghosh M, Renders S, Correia N, Donato E, Dixon KO, Hirche C, Andresen C, Robens C, Werner PS, Boch T, Eisel D, Osen W, Pilz F, Przybylla A, Klein C, Buchholz F, Milsom MD, Essers MAG, Eichmuller SB, Hofmann WK, Nowak D, Hubschmann D, Hundemer M, Thiede C, Bullinger L, Muller-Tidow C, Armstrong SA, Trumpp A, Kuchroo VK, Haas S. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell. 2022;29(5):760-775 e710.

17. Herbig M, Jacobi A, Wobus M, Weidner H, Mies A, Krater M, Otto O, Thiede C, Weickert MT, Gotze KS, Rauner M, Hofbauer LC, Bornhauser M, Guck J, Ader M, Platzbecker U, Balaian E. Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes. Sci Rep. 2022;12(1):870.

18. He L, Arnold C, Thoma J, Rohde C, Kholmatov M, Garg S, Hsiao CC, Viol L, Zhang K, Sun R, Schmidt C, Janssen M, MacRae T, Huber K, Thiede C, Hebert J, Sauvageau G, Spratte J, Fluhr H, Aust G, Muller-Tidow C, Niehrs C, Pereira G, Hamann J, Tanaka M, Zaugg JB, Pabst C. CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia. EMBO Mol Med. 2022;14(4):e14990.

19. Georgi JA, Stasik S, Bornhauser M, Platzbecker U, Thiede C. Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML. Front Oncol. 2022;12:841608.

20. Folprecht G, Reinacher-Schick A, Weitz J, Lugnier C, Kraeft AL, Wisser S, Aust DE, Weiss L, von Bubnoff N, Kramer M, Thiede C, Tannapfel A. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clin Colorectal Cancer. 2022;21(2):170-174.

21. Fleischmann M, Scholl S, Frietsch JJ, Hilgendorf I, Schrenk K, Hammersen J, Prims F, Thiede C, Hochhaus A, Schnetzke U. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol. 2022.

22. Eckardt JN, Stolzel F, Kunadt D, Rollig C, Stasik S, Wagenfuhr L, Johrens K, Kuithan F, Kramer A, Scholl S, Hochhaus A, Crysandt M, Brummendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schafer-Eckart K, Schliemann C, Krause SW, Herbst R, Hanel M, Hanoun M, Kaiser U, Kaufmann M, Racil Z, Mayer J, Kroschinsky F, Berdel WE, Ehninger G, Serve H, Muller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Bornhauser M, Thiede C, Middeke JM. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. J Hematol Oncol. 2022;15(1):60.

23. Eckardt JN, Schmittmann T, Riechert S, Kramer M, Sulaiman AS, Sockel K, Kroschinsky F, Schetelig J, Wagenfuhr L, Schuler U, Platzbecker U, Thiede C, Stolzel F, Rollig C, Bornhauser M, Wendt K, Middeke JM. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. BMC Cancer. 2022;22(1):201.

24. Eckardt JN, Middeke JM, Riechert S, Schmittmann T, Sulaiman AS, Kramer M, Sockel K, Kroschinsky F, Schuler U, Schetelig J, Rollig C, Thiede C, Wendt K, Bornhauser M. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. Leukemia. 2022;36(1):111-118.

25. Bozic T, Kuo CC, Hapala J, Franzen J, Eipel M, Platzbecker U, Kirschner M, Beier F, Jost E, Thiede C, Wagner W. Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns. Leukemia. 2022;36(1):80-89.